Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
BofA to hold a virtual conference » 09:36
05/11/21
05/11
09:36
05/11/21
09:36
ADCT

ADC Therapeutics

$22.44 /

-1.15 (-4.87%)

, ADMS

Adamas Pharmaceuticals

$4.96 /

-0.2 (-3.88%)

, AVTR

Avantor

$30.48 /

-0.725 (-2.32%)

, CCRN

Cross Country Healthcare

$17.16 /

+0.26 (+1.54%)

, FIXX

Homology Medicines

$6.39 /

-0.13 (-1.99%)

, IMTX

Immatics

$10.81 /

-0.77 (-6.65%)

, ISRG

Intuitive Surgical

$835.60 /

-21.9 (-2.55%)

, ITCI

Intra-Cellular

$35.97 /

+1.01 (+2.89%)

, JAZZ

Jazz Pharmaceuticals

$176.02 /

+1.35 (+0.77%)

, JNJ

Johnson & Johnson

$170.32 /

+1.68 (+1.00%)

, LLY

Eli Lilly

$194.82 /

-0.75 (-0.38%)

, TVTX

Travere Therapeutics

$19.78 /

-0.23 (-1.15%)

, QGEN

Qiagen

$46.90 /

-0.75 (-1.57%)

, PTCT

PTC Therapeutics

$38.88 /

-1.34 (-3.33%)

, PHG

Philips

$56.39 /

-1.016893 (-1.77%)

, SWAV

ShockWave Medical

$134.82 /

-12.73 (-8.63%)

, RLAY

Relay Therapeutics

$27.69 /

-1.8 (-6.10%)

, ZBH

Zimmer Biomet

$171.99 /

-0.575 (-0.33%)

, WST

West Pharmaceutical

$333.76 /

-0.36 (-0.11%)

, NVRO

Nevro

$155.00 /

-1.15 (-0.74%)

, HUM

Humana

$470.07 /

+5.45 (+1.17%)

, DHR

Danaher

$259.10 /

+0.8 (+0.31%)

Bank of America Merrill…

Bank of America Merrill Lynch Virtual Healthcare Conference will be held on May 11-13.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

TVTX Travere Therapeutics
$19.78 /

-0.23 (-1.15%)

SWAV ShockWave Medical
$134.82 /

-12.73 (-8.63%)

RLAY Relay Therapeutics
$27.69 /

-1.8 (-6.10%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

PTCT PTC Therapeutics
$38.88 /

-1.34 (-3.33%)

PHG Philips
$56.39 /

-1.016893 (-1.77%)

NVRO Nevro
$155.00 /

-1.15 (-0.74%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

ITCI Intra-Cellular
$35.97 /

+1.01 (+2.89%)

ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

IMTX Immatics
$10.81 /

-0.77 (-6.65%)

HUM Humana
$470.07 /

+5.45 (+1.17%)

FIXX Homology Medicines
$6.39 /

-0.13 (-1.99%)

DHR Danaher
$259.10 /

+0.8 (+0.31%)

CCRN Cross Country Healthcare
$17.16 /

+0.26 (+1.54%)

AVTR Avantor
$30.48 /

-0.725 (-2.32%)

ADMS Adamas Pharmaceuticals
$4.96 /

-0.2 (-3.88%)

ADCT ADC Therapeutics
$22.44 /

-1.15 (-4.87%)

ADCT ADC Therapeutics
$22.44 /

-1.15 (-4.87%)

04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
10/29/20
Fly Intel: Top five analyst initiations
ADMS Adamas Pharmaceuticals
$4.96 /

-0.2 (-3.88%)

02/02/21 H.C. Wainwright
Adamas Pharmaceuticals price target raised to $12 from $10 at H.C. Wainwright
02/01/21 JMP Securities
Adamas settlement brings 'robust' patent exclusivity, says JMP Securities
01/28/21 Northland
Adamas Pharmaceuticals price target raised to $12.50 from $7.50 at Northland
AVTR Avantor
$30.48 /

-0.725 (-2.32%)

04/29/21 JPMorgan
Avantor price target raised to $40 from $35 at JPMorgan
04/29/21 Baird
Avantor price target raised to $36 from $32 at Baird
04/29/21 Stifel
Avantor upgraded to Buy after 'strong' Q1 report at Stifel
04/29/21 Stifel
Avantor upgraded to Buy from Hold at Stifel
CCRN Cross Country Healthcare
$17.16 /

+0.26 (+1.54%)

05/06/21 Benchmark
Cross Country Healthcare downgraded to Hold from Buy at Benchmark
03/09/21 Barrington
Barrington ups Cross Country Healthcare target to $14 after quarterly results
11/25/20 Barrington
Cross Country Healthcare target raised to $12 at Barrington after Q3 results
11/23/20 BMO Capital
BMO upgrades Cross Country Healthcare to Outperform on success of turnaround
FIXX Homology Medicines
$6.39 /

-0.13 (-1.99%)

05/07/21 Oppenheimer
Homology Medicines price target lowered to $24 from $27 at Oppenheimer
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
IMTX Immatics
$10.81 /

-0.77 (-6.65%)

03/17/21 Chardan
Immatics' early TCR platform activity signals 'notable,' says Chardan
03/17/21 SVB Leerink
Immatics price target raised to $26 from $17 at SVB Leerink
11/20/20 BofA
Immatics initiated with a Buy at BofA
09/21/20 Goldman Sachs
Immatics initiated with a Buy at Goldman Sachs
ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

04/21/21 SVB Leerink
Intuitive Surgical price target raised to $860 from $825 at SVB Leerink
04/21/21 Wells Fargo
Intuitive Surgical price target raised to $892 from $879 at Wells Fargo
04/21/21 Deutsche Bank
Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank
04/21/21 JPMorgan
Intuitive Surgical price target raised to $900 from $840 at JPMorgan
ITCI Intra-Cellular
$35.97 /

+1.01 (+2.89%)

12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
12/15/20
Fly Intel: Top five analyst initiations
12/15/20 BofA
Intra-Cellular initiated with a Buy at BofA
12/10/20
Fly Intel: Top five analyst initiations
JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
04/14/21 Stifel
Jazz Pharmaceuticals price target raised to $202 from $195 at Stifel
04/06/21 RBC Capital
Jazz Pharmaceuticals transferred with an Outperform at RBC Capital
04/01/21 Morgan Stanley
Jazz Pharmaceuticals price target raised to $176 from $162 at Morgan Stanley
JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

05/05/21 Argus
Emergent BioSolutions downgraded to Hold from Buy at Argus
04/29/21 Wells Fargo
Boston Scientific price target raised to $50 from $42 at Wells Fargo
04/26/21 B. Riley
B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments
04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
TVTX Travere Therapeutics
$19.78 /

-0.23 (-1.15%)

05/07/21 BMO Capital
Travere Therapeutics price target lowered to $38 from $43 at BMO Capital
04/12/21 Wedbush
Travere Therapeutics price target lowered to $39 from $46 at Wedbush
03/02/21 BMO Capital
Travere Therapeutics price target lowered to $43 from $48 at BMO Capital
02/16/21 Barclays
Travere Therapeutics assumed with an Overweight at Barclays
QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
PTCT PTC Therapeutics
$38.88 /

-1.34 (-3.33%)

04/26/21 Credit Suisse
PTC Therapeutics assumed with a Neutral at Credit Suisse
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
PHG Philips
$56.39 /

-1.016893 (-1.77%)

04/29/21 Berenberg
Philips price target raised to EUR 52 from EUR 50 at Berenberg
04/28/21 Credit Suisse
Philips price target raised to EUR 49 from EUR 45 at Credit Suisse
04/27/21 UBS
Philips price target raised to EUR 56 from EUR 54 at UBS
03/23/21 Barclays
Philips price target raised to EUR 55 from EUR 54 at Barclays
SWAV ShockWave Medical
$134.82 /

-12.73 (-8.63%)

05/11/21 Wells Fargo
ShockWave Medical price target raised to $161 from $151 at Wells Fargo
05/11/21 BofA
ShockWave Medical upgraded to Buy at BofA after guidance hike
05/11/21 BofA
ShockWave Medical upgraded to Buy from Neutral at BofA
05/11/21 Piper Sandler
ShockWave Medical upgraded to Overweight from Neutral at Piper Sandler
RLAY Relay Therapeutics
$27.69 /

-1.8 (-6.10%)

03/29/21 JMP Securities
Relay Therapeutics price target lowered to $50 from $66 at JMP Securities
01/29/21 JPMorgan
Relay Therapeutics price target raised to $52 from $36 at JPMorgan
12/15/20 H.C. Wainwright
Relay Therapeutics price target raised to $57 from $54 at H.C. Wainwright
12/08/20 JMP Securities
Relay Therapeutics initiated with an Outperform at JMP Securities
ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

05/11/21 JMP Securities
Zimmer Biomet price target raised to $195 from $180 at JMP Securities
05/05/21 Truist
Zimmer Biomet price target raised to $188 from $174 at Truist
05/05/21 Oppenheimer
Zimmer Biomet price target raised to $195 from $185 at Oppenheimer
04/09/21 Northland
Zimmer Biomet upgraded to Outperform from Market Perform at Northland
WST West Pharmaceutical
$333.76 /

-0.36 (-0.11%)

11/09/20 KeyBanc
West Pharmaceutical initiated with an Overweight at KeyBanc
10/13/20 Stephens
West Pharmaceutical initiated with an Equal Weight at Stephens
07/21/20 BofA
West Pharmaceutical upgraded to Buy on COVID-related tailwinds at BofA
07/21/20 BofA
West Pharmaceutical upgraded to Buy from Neutral at BofA
NVRO Nevro
$155.00 /

-1.15 (-0.74%)

05/06/21 Canaccord
Nevro price target raised to $225 from $217 at Canaccord
04/05/21 Piper Sandler
Nevro publication in JAMA Neurology helps add credibility, says Piper Sandler
02/25/21 Canaccord
Nevro price target raised to $217 from $203 at Canaccord
02/02/21
Fly Intel: Top five analyst initiations
HUM Humana
$470.07 /

+5.45 (+1.17%)

04/29/21 Oppenheimer
Humana price target raised to $480 from $460 at Oppenheimer
04/29/21 Mizuho
Humana price target raised to $480 from $462 at Mizuho
04/29/21 Citi
Humana price target raised to $510 from $496 at Citi
04/16/21 Stephens
Humana named a new Best Idea for 2021 at Stephens
DHR Danaher
$259.10 /

+0.8 (+0.31%)

04/26/21 Barclays
Danaher price target raised to $300 from $265 at Barclays
04/23/21 Jefferies
Danaher price target raised to $290 from $270 at Jefferies
04/23/21 Baird
Danaher price target raised to $270 from $249 at Baird
04/23/21 Wells Fargo
Danaher price target raised to $280 from $260 at Wells Fargo
ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

WST West Pharmaceutical
$333.76 /

-0.36 (-0.11%)

TVTX Travere Therapeutics
$19.78 /

-0.23 (-1.15%)

SWAV ShockWave Medical
$134.82 /

-12.73 (-8.63%)

RLAY Relay Therapeutics
$27.69 /

-1.8 (-6.10%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

PTCT PTC Therapeutics
$38.88 /

-1.34 (-3.33%)

PHG Philips
$56.39 /

-1.016893 (-1.77%)

NVRO Nevro
$155.00 /

-1.15 (-0.74%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

ITCI Intra-Cellular
$35.97 /

+1.01 (+2.89%)

ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

IMTX Immatics
$10.81 /

-0.77 (-6.65%)

HUM Humana
$470.07 /

+5.45 (+1.17%)

FIXX Homology Medicines
$6.39 /

-0.13 (-1.99%)

DHR Danaher
$259.10 /

+0.8 (+0.31%)

CCRN Cross Country Healthcare
$17.16 /

+0.26 (+1.54%)

AVTR Avantor
$30.48 /

-0.725 (-2.32%)

ADMS Adamas Pharmaceuticals
$4.96 /

-0.2 (-3.88%)

ADCT ADC Therapeutics
$22.44 /

-1.15 (-4.87%)

  • 07
    Apr
  • 25
    Feb
  • 12
    Feb
  • 06
    Nov
  • 24
    Sep
  • 11
    Sep
  • 20
    Aug
  • 16
    Jul
  • 17
    Jun
  • 21
    May
  • 15
    May
QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

PHG Philips
$56.39 /

-1.016893 (-1.77%)

NVRO Nevro
$155.00 /

-1.15 (-0.74%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

DHR Danaher
$259.10 /

+0.8 (+0.31%)

ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

SWAV ShockWave Medical
$134.82 /

-12.73 (-8.63%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

PTCT PTC Therapeutics
$38.88 /

-1.34 (-3.33%)

PHG Philips
$56.39 /

-1.016893 (-1.77%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

IMTX Immatics
$10.81 /

-0.77 (-6.65%)

HUM Humana
$470.07 /

+5.45 (+1.17%)

FIXX Homology Medicines
$6.39 /

-0.13 (-1.99%)

CCRN Cross Country Healthcare
$17.16 /

+0.26 (+1.54%)

ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

TVTX Travere Therapeutics
$19.78 /

-0.23 (-1.15%)

RLAY Relay Therapeutics
$27.69 /

-1.8 (-6.10%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

DHR Danaher
$259.10 /

+0.8 (+0.31%)

Over a week ago
Hot Stocks
Intuitive Surgical appoint Monica Reed to board of directors » 08:51
04/26/21
04/26
08:51
04/26/21
08:51
ISRG

Intuitive Surgical

$875.69 /

+16.06 (+1.87%)

Intuitive announced the…

Intuitive announced the appointment of Dr. Monica Reed, a former AdventHealth executive, to its board of directors effective April 22, 2021. "Dr. Reed brings decades of leadership insight, experience, and accomplishments in hospital and health system administration that will complement our existing board," said Intuitive CEO Gary Guthart. "We look forward to her contributions as we continue to improve how we serve our surgeon, hospital, and healthcare system customers in this rapidly evolving healthcare environment."

ShowHide Related Items >><<
ISRG Intuitive Surgical
$875.69 /

+16.06 (+1.87%)

ISRG Intuitive Surgical
$875.69 /

+16.06 (+1.87%)

04/21/21 SVB Leerink
Intuitive Surgical price target raised to $860 from $825 at SVB Leerink
04/21/21 Wells Fargo
Intuitive Surgical price target raised to $892 from $879 at Wells Fargo
04/21/21 Deutsche Bank
Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank
04/21/21 JPMorgan
Intuitive Surgical price target raised to $900 from $840 at JPMorgan
ISRG Intuitive Surgical
$875.69 /

+16.06 (+1.87%)

ISRG Intuitive Surgical
$875.69 /

+16.06 (+1.87%)

ISRG Intuitive Surgical
$875.69 /

+16.06 (+1.87%)

Options
Early notable gainers among liquid option names on April 21st » 09:55
04/21/21
04/21
09:55
04/21/21
09:55
ISRG

Intuitive Surgical

$847.01 /

+35.02 (+4.31%)

, NCLH

Norwegian Cruise Line

$27.84 /

+1.09 (+4.07%)

, CTXS

Citrix

$141.96 /

+3.84 (+2.78%)

, DISH

Dish

$37.58 /

+0.69 (+1.87%)

, EW

Edwards Lifesciences

$92.83 /

+3.21 (+3.58%)

Notable gainers among…

Notable gainers among liquid option names this morning include Intuitive Surgical (ISRG) $863.24 +50.95, Norwegian Cruise Line (NCLH) $28.38 +1.63, Citrix (CTXS) $143.56 +5.35, Dish Network (DISH) $38.21 +1.33, and Edwards Lifesciences (EW) $92.79 +3.16.

ShowHide Related Items >><<
NCLH Norwegian Cruise Line
$27.84 /

+1.09 (+4.07%)

ISRG Intuitive Surgical
$847.01 /

+35.02 (+4.31%)

EW Edwards Lifesciences
$92.83 /

+3.21 (+3.58%)

DISH Dish
$37.58 /

+0.69 (+1.87%)

CTXS Citrix
$141.96 /

+3.84 (+2.78%)

ISRG Intuitive Surgical
$847.01 /

+35.02 (+4.31%)

04/21/21 SVB Leerink
Intuitive Surgical price target raised to $860 from $825 at SVB Leerink
04/21/21 Wells Fargo
Intuitive Surgical price target raised to $892 from $879 at Wells Fargo
04/21/21 Deutsche Bank
Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank
04/21/21 JPMorgan
Intuitive Surgical price target raised to $900 from $840 at JPMorgan
NCLH Norwegian Cruise Line
$27.84 /

+1.09 (+4.07%)

04/20/21 Goldman Sachs
Norwegian Cruise Line upgraded to Buy from Neutral at Goldman Sachs
03/24/21 Stifel
Cruiseline stock selloff 'unwarranted,' says Stifel
03/18/21 UBS
Norwegian Cruise Line price target raised to $32 from $21 at UBS
03/16/21 JPMorgan
Norwegian Cruise Line price target raised to $36 from $33 at JPMorgan
CTXS Citrix
$141.96 /

+3.84 (+2.78%)

04/21/21
Fly Intel: Top five analyst upgrades
04/21/21 Jefferies
Citrix upgraded to Buy from Hold at Jefferies
04/13/21 BofA
Citrix reinstated with an Underperform at BofA
03/03/21 Citi
Citrix assumed with a Buy at Citi
DISH Dish
$37.58 /

+0.69 (+1.87%)

03/08/21 Citi
Dish could pursue deal for TDS or U.S. Cellular for rural coverage, says Citi
02/25/21 Oppenheimer
Verizon, AT&T downgraded to Perform on valuation at Oppenheimer
02/23/21
Fly Intel: Top five analyst downgrades
02/23/21 Pivotal Research
Dish downgraded to Hold from Buy at Pivotal Research
EW Edwards Lifesciences
$92.83 /

+3.21 (+3.58%)

04/21/21 Raymond James
Edwards Lifesciences price target raised to $101 from $96 at Raymond James
04/21/21 Wells Fargo
Edwards Lifesciences price target raised to $93 from $87 at Wells Fargo
04/21/21 Canaccord
Edwards Lifesciences price target raised to $103 from $94 at Canaccord
04/21/21 Piper Sandler
Edwards Lifesciences price target raised to $105 from $97 at Piper Sandler
NCLH Norwegian Cruise Line
$27.84 /

+1.09 (+4.07%)

ISRG Intuitive Surgical
$847.01 /

+35.02 (+4.31%)

EW Edwards Lifesciences
$92.83 /

+3.21 (+3.58%)

DISH Dish
$37.58 /

+0.69 (+1.87%)

CTXS Citrix
$141.96 /

+3.84 (+2.78%)

  • 05
    Mar
  • 18
    Nov
  • 17
    Jul
  • 06
    May
NCLH Norwegian Cruise Line
$27.84 /

+1.09 (+4.07%)

DISH Dish
$37.58 /

+0.69 (+1.87%)

NCLH Norwegian Cruise Line
$27.84 /

+1.09 (+4.07%)

ISRG Intuitive Surgical
$847.01 /

+35.02 (+4.31%)

EW Edwards Lifesciences
$92.83 /

+3.21 (+3.58%)

DISH Dish
$37.58 /

+0.69 (+1.87%)

NCLH Norwegian Cruise Line
$27.84 /

+1.09 (+4.07%)

ISRG Intuitive Surgical
$847.01 /

+35.02 (+4.31%)

EW Edwards Lifesciences
$92.83 /

+3.21 (+3.58%)

DISH Dish
$37.58 /

+0.69 (+1.87%)

Recommendations
Intuitive Surgical price target raised to $860 from $825 at SVB Leerink » 08:34
04/21/21
04/21
08:34
04/21/21
08:34
ISRG

Intuitive Surgical

$809.85 /

-0.91 (-0.11%)

SVB Leerink analyst…

SVB Leerink analyst Richard Newitter raised the firm's price target on Intuitive Surgical to $860 from $825 and keeps a Market Perform rating on the shares. Coming off a "solid" Q1 beat, the analysst continues to view Intuitive Surgical as a premium MedTech asset. However, he stays on the sidelines given an already big valuation premium, as he favors other MedTech growth stocks in his universe with equal/better growth profiles relative to their multiple, and as he sees less expensive ways to play a COVID recovery with better risk-reward.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

04/21/21 Wells Fargo
Intuitive Surgical price target raised to $892 from $879 at Wells Fargo
04/21/21 Deutsche Bank
Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank
04/21/21 JPMorgan
Intuitive Surgical price target raised to $900 from $840 at JPMorgan
04/21/21 Baird
Baird upgrades Intuitive Surgical following guidance reinstatement
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

Recommendations
Intuitive Surgical price target raised to $892 from $879 at Wells Fargo » 08:06
04/21/21
04/21
08:06
04/21/21
08:06
ISRG

Intuitive Surgical

$809.85 /

-0.91 (-0.11%)

Wells Fargo analyst…

Wells Fargo analyst Lawrence Biegelsen raised the firm's price target on Intuitive Surgical to $892 from $879 and keeps an Overweight rating on the shares following quarterly results. The analyst notes the company reported Q1 results that exceeded expectations and issued formal 2021 guidance for the first time.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

04/21/21 Deutsche Bank
Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank
04/21/21 JPMorgan
Intuitive Surgical price target raised to $900 from $840 at JPMorgan
04/21/21 Baird
Baird upgrades Intuitive Surgical following guidance reinstatement
04/21/21 Citi
Intuitive Surgical price target raised to $939 from $862 at Citi
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

Recommendations
Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank » 07:35
04/21/21
04/21
07:35
04/21/21
07:35
ISRG

Intuitive Surgical

$809.85 /

-0.91 (-0.11%)

Deutsche Bank analyst…

Deutsche Bank analyst Imron Zafar raised the firm's price target on Intuitive Surgical to $825 from $690 and keeps a Hold rating on the shares. The company last night reported an "all-around high-quality" Q1, comfortably outperforming Street expectations across the board, Zafar tells investors in a research note.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

04/21/21 JPMorgan
Intuitive Surgical price target raised to $900 from $840 at JPMorgan
04/21/21 Baird
Baird upgrades Intuitive Surgical following guidance reinstatement
04/21/21 Citi
Intuitive Surgical price target raised to $939 from $862 at Citi
04/21/21 Oppenheimer
Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

Recommendations
Intuitive Surgical price target raised to $900 from $840 at JPMorgan » 07:25
04/21/21
04/21
07:25
04/21/21
07:25
ISRG

Intuitive Surgical

$809.85 /

-0.91 (-0.11%)

JPMorgan analyst Tycho…

JPMorgan analyst Tycho Peterson raised the firm's price target on Intuitive Surgical to $900 from $840 and reiterates an Overweight rating on the shares. The company's "impressive" Q1 showcased an encouraging rebound in procedures and an improving capex outlook, Peterson tells investors in a research note. The analyst continues to view the rollout of flexible financing programs, combined with disciplined investments, as "smart moves to accelerate the post-pandemic recovery and grow the competitive moat ahead of new entrants."

ShowHide Related Items >><<
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

04/21/21 Baird
Baird upgrades Intuitive Surgical following guidance reinstatement
04/21/21 Citi
Intuitive Surgical price target raised to $939 from $862 at Citi
04/21/21 Oppenheimer
Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer
04/21/21 Baird
Intuitive Surgical upgraded to Outperform from Neutral at Baird
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

Upgrade
Baird upgrades Intuitive Surgical following guidance reinstatement » 06:50
04/21/21
04/21
06:50
04/21/21
06:50
ISRG

Intuitive Surgical

/

+

As reported previously,…

As reported previously, Baird analyst Mike Polark upgraded Intuitive Surgical to Outperform from Neutral with a price target of $925, up from $825. The analyst noted the company "smashed" Q1 estimates and reinstated guidance for the first time since the pandemic started. He said forward comps are extraordinarily easy. volumes improved, and going forward he continues to believes the company is good is still innovating.

ShowHide Related Items >><<
ISRG Intuitive Surgical
/

+

ISRG Intuitive Surgical
/

+

04/21/21 Citi
Intuitive Surgical price target raised to $939 from $862 at Citi
04/21/21 Oppenheimer
Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer
04/21/21 Baird
Intuitive Surgical upgraded to Outperform from Neutral at Baird
04/21/21 Piper Sandler
Intuitive Surgical price target raised to $840 from $735 at Piper Sandler
ISRG Intuitive Surgical
/

+

ISRG Intuitive Surgical
/

+

ISRG Intuitive Surgical
/

+

Recommendations
Intuitive Surgical price target raised to $939 from $862 at Citi » 06:31
04/21/21
04/21
06:31
04/21/21
06:31
ISRG

Intuitive Surgical

$809.85 /

-0.91 (-0.11%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch raised the firm's price target on Intuitive Surgical to $939 from $862 and reiterates a Buy rating on the shares. The company's Q1 was better than expected, reflecting a recovery in procedure volumes and daVinci placements, Wuensch tells investors in a research note.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

04/21/21 Oppenheimer
Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer
04/21/21 Baird
Intuitive Surgical upgraded to Outperform from Neutral at Baird
04/21/21 Piper Sandler
Intuitive Surgical price target raised to $840 from $735 at Piper Sandler
04/05/21 Evercore ISI
Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

Upgrade
Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer » 06:12
04/21/21
04/21
06:12
04/21/21
06:12
ISRG

Intuitive Surgical

$809.85 /

-0.91 (-0.11%)

Oppenheimer analyst Suraj…

Oppenheimer analyst Suraj Kalia upgraded Intuitive Surgical to Perform from Underperform without a price target, citing the company's "strong" Q1 and outlook. Fiscal 2021 procedure growth guidance was introduced at 22%-26%, well ahead of Street's 18% estimate, on U.S. general surgery and earlier-stage outside the U.S. markets, Kalia tells investors in a research note. The analyst now sees a better post-Covid outlook for Intuitive Surgical.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

04/21/21 Baird
Intuitive Surgical upgraded to Outperform from Neutral at Baird
04/21/21 Piper Sandler
Intuitive Surgical price target raised to $840 from $735 at Piper Sandler
04/05/21 Evercore ISI
Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
04/01/21
Fly Intel: Top five analyst initiations
ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

ISRG Intuitive Surgical
$809.85 /

-0.91 (-0.11%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.